Aliases & Classifications for Leukemia

Summaries for Leukemia

MedlinePlus : 41 leukemia is cancer of the white blood cells. white blood cells help your body fight infection. your blood cells form in your bone marrow. in leukemia, the bone marrow produces abnormal white blood cells. these cells crowd out the healthy blood cells, making it hard for blood to do its work. there are different types of leukemia, including acute lymphocytic leukemia acute myeloid leukemia chronic lymphocytic leukemia chronic myeloid leukemia leukemia can develop quickly or slowly. chronic leukemia grows slowly. in acute leukemia, the cells are very abnormal and their number increases rapidly. adults can get either type; children with leukemia most often have an acute type. some leukemias can often be cured. other types are hard to cure, but you can often control them. treatments may include chemotherapy, radiation and stem cell transplantation. even if symptoms disappear, you might need therapy to prevent a relapse. nih: national cancer institute

MalaCards based summary : Leukemia is related to leukemia, acute myeloid and acute myeloid leukemia with recurrent genetic anomaly, and has symptoms including angina pectoris, chest pain and edema. An important gene associated with Leukemia is FLT3 (Fms Related Tyrosine Kinase 3), and among its related pathways/superpathways are Cytokine Signaling in Immune system and Pathways in cancer. The drugs Arranon and Arzerra have been mentioned in the context of this disorder. Affiliated tissues include myeloid, t cells and b cells, and related phenotypes are Increased HDAC inhibitor resistance and cellular

Disease Ontology : 12 A cancer that affects the blood or bone marrow characterized by an abnormal proliferation of blood cells.

Wikipedia : 72 Leukemia, also spelled leukaemia, is a group of cancers that usually begin in the bone marrow and result... more...

Related Diseases for Leukemia

Diseases in the Leukemia family:

Acute Leukemia Chronic Leukemia
Subacute Leukemia

Diseases related to Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1181)
id Related Disease Score Top Affiliating Genes
1 leukemia, acute myeloid 34.4 FLT3 MLF1 NPM1 PTPN11 RUNX1
2 acute myeloid leukemia with recurrent genetic anomaly 34.1 FLT3 NPM1
3 acute myeloid leukemia with inv3(p21;q26.2) or t(3;3)(p21;q26.2) 33.9 FLT3 NPM1
4 acute pre-b-cell lymphoblastic leukemia 33.6 FLT3 NPM1
5 hemolytic anemia 31.3 ABL1 FLT3 NPM1 PTPN11 RUNX1
6 acute myocardial infarction 30.3 MCL1 RUNX1 TAL1 TAL2
7 chronic lymphocytic leukemia 12.3
8 leukemia, acute lymphoblastic 12.2
9 myeloid leukemia 12.2
10 juvenile myelomonocytic leukemia 12.2
11 hairy cell leukemia 12.2
12 childhood leukemia 12.2
13 megakaryocytic leukemia 12.2
14 acute leukemia 12.1
15 leukemia, chronic myeloid, somatic 12.1
16 acute lymphocytic leukemia 12.1
17 adult t-cell leukemia 12.1
18 mast-cell leukemia 12.1
19 acute monocytic leukemia 12.1
20 leukemia, acute promyelocytic, somatic 12.1
21 t-cell prolymphocytic leukemia 12.1
22 lymphoblastic leukemia 12.1
23 atypical chronic myeloid leukemia 12.1
24 chronic myelomonocytic leukemia 12.1
25 prolymphocytic leukemia 12.1
26 monocytic leukemia 12.0
27 plasma cell leukemia 12.0
28 lymphoid leukemia 12.0
29 acute monoblastic leukemia 12.0
30 cytogenetically normal acute myeloid leukemia 12.0
31 large granular lymphocyte leukemia 12.0
32 chronic leukemia 12.0
33 chronic neutrophilic leukemia 12.0
34 acute erythroid leukemia 12.0
35 t-cell large granular lymphocyte leukemia 12.0
36 core binding factor acute myeloid leukemia 12.0
37 b cell prolymphocytic leukemia 12.0
38 human t-cell leukemia virus type 1 11.9
39 acute myeloblastic leukemia with maturation 11.9
40 acute myeloblastic leukemia without maturation 11.9
41 chronic eosinophilic leukemia 11.9
42 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 11.9
43 acute lymphoblastic leukemia, childhood 11.9
44 familial acute myeloid leukemia with mutated cebpa 11.9
45 noonan syndrome-like disorder with or without juvenile myelomonocytic leukemia 11.9
46 t-cell leukemia 11.9
47 acute basophilic leukemia 11.9
48 subacute leukemia 11.9
49 pdgfrb-associated chronic eosinophilic leukemia 11.9
50 pdgfra-associated chronic eosinophilic leukemia 11.9

Comorbidity relations with Leukemia via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia
Heart Disease Leukemia, B-Cell, Chronic

Graphical network of the top 20 diseases related to Leukemia:



Diseases related to Leukemia

Symptoms & Phenotypes for Leukemia

UMLS symptoms related to Leukemia:


angina pectoris, chest pain, edema

GenomeRNAi Phenotypes related to Leukemia according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased HDAC inhibitor resistance GR00115-A-0 8.62 LIF LIFR

MGI Mouse Phenotypes related to Leukemia:

44 (show all 14)
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.37 ABL1 ABL2 FLI1 FLT3 LIF MCL1
2 hematopoietic system MP:0005397 10.36 ABL1 FLI1 FLT3 LIF LIFR LYL1
3 embryo MP:0005380 10.29 ABL1 ABL2 FLI1 LIF LIFR MCL1
4 growth/size/body region MP:0005378 10.29 ABL1 ABL2 FLI1 FLT3 LIF LIFR
5 immune system MP:0005387 10.28 FLI1 FLT3 LIF LIFR LYL1 MCL1
6 homeostasis/metabolism MP:0005376 10.25 ABL1 ABL2 FLT3 HLF LIF LIFR
7 cardiovascular system MP:0005385 10.24 ABL1 ABL2 FLI1 LIF NPM1 PBX1
8 endocrine/exocrine gland MP:0005379 10.19 MCL1 PBX1 PTPN11 RAF1 RUNX1 ZBTB16
9 mortality/aging MP:0010768 10.16 FLI1 FLT3 HLF LIF LIFR MCL1
10 integument MP:0010771 9.97 LIF MCL1 NPM1 PBX1 PTPN11 RAF1
11 liver/biliary system MP:0005370 9.97 ABL1 FLI1 LIF LIFR NPM1 PBX1
12 nervous system MP:0003631 9.77 ABL1 ABL2 FLI1 HLF LIF LIFR
13 neoplasm MP:0002006 9.76 ZBTB16 FLI1 FLT3 NPM1 PML PTPN11
14 skeleton MP:0005390 9.32 ABL1 FLT3 LIF LIFR PBX1 PTPN11

Drugs & Therapeutics for Leukemia

FDA approved drugs:

(show all 30)
id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Arranon 17 46 NELARABINE GlaxoSmithKline October 2005
2
Arzerra 17 46 OFATUMUMAB GlaxoSmithKline October 2009
3
Blincyto 17 46 BLINATUMOMAB Amgen December 2014
4
Bosulif 17 46 BOSUTINIB MONOHYDRATE Pfizer September 2012
5
Busulfex 17 46 BUSULFAN Orphan Medical February 1999
6
Campath 17 46 ALEMTUZUMAB Berlex Laboratories May 2001
7
Clolar 17 46 CLOFARABINE Genzyme December, 2004
8
Elitek 17 46 RASBURICASE sanofi-aventis October 2009
9
Elliotts B Solution 17 CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE Orphan Medical October 1996
10
Erwinaze 17 46 asparaginase Erwinia chrysanthemi Eusa Pharma November of 2011
11
Gazyva 17 46 OBINUTUZUMAB Genentech October of 2013
12
Gleevec 17 46 IMATINIB MESYLATE Novartis May 2001
13
Iclusig 17 46 PONATINIB HYDROCHLORIDE Ariad Pharmaceuticals December 2012
14
Imbruvica 17 46 IBRUTINIB Pharmacyclics November of 2013/February 2014
15
Intron A 17 46 INTERFERON ALFA-2B Schering-Plough December 1997/ December 1995/ March 1997
16
Leukine 17 SARGRAMOSTIM Immunex on November 24, 1995/ November 1996
17
Lynparza 17 46 OLAPARIB AstraZeneca December 2014
18
Marqibo 17 46 VINCRISTINE SULFATE Talon Therapeutics August 2012
19
Mylotarg 17 46 GEMTUZUMAB OZOGAMICIN Wyeth May 2000
20
Neupogen 17 46 FILGRASTIM Amgen Approval April 1998
21
Pomalyst 17 46 POMALIDOMIDE Celgene February 2013
22
Revlimid 17 46 LENALIDOMIDE Celgene June 2013
23
Rituxan 17 46 RITUXIMAB Biogen IDEC, Genentech November 1997
24
Sprycel 17 46 DASATINIB Bristol-Myers Squibb June 2006
25
Sutent 17 46 SUNITINIB MALATE Pfizer May 2011/ January 2006
26
Synribo 17 46 OMACETAXINE MEPESUCCINATE Teva Pharmaceutical October 2012
27
Tasigna 17 46 NILOTINIB HYDROCHLORIDE MONOHYDRATE Novartis October 2007
28
Treanda 17 46 BENDAMUSTINE HYDROCHLORIDE Cephalon October 2008
29
Trisenox 17 46 ARSENIC TRIOXIDE Cell Therapeutics September 2000
30
Zydelig 17 46 IDELALISIB Gilead July 2014

Drugs for Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 919)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cytarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 147-94-4 6253
2
Daunorubicin Approved Phase 4,Phase 3,Phase 2,Phase 1 20830-81-3 30323
3
Idarubicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 58957-92-9 42890
4
Mitoxantrone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 65271-80-9 4212
5
Arsenic trioxide Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 1327-53-3 518740
6
Adenosine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 58-61-7 60961
7
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
8
Pentostatin Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 53910-25-1 40926 439693
9
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 174722-31-7 10201696
10
Fludarabine Approved Phase 4,Phase 3,Phase 2,Phase 1 21679-14-1, 75607-67-9 30751
11
Vidarabine Approved Phase 4,Phase 3,Phase 2,Phase 1 24356-66-9 32326 21704
12
Asparaginase Approved Phase 4,Phase 3,Phase 2,Phase 1 9015-68-3
13
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-02-2 5743
14
Lenograstim Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 135968-09-1
15
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 1959-05-2, 59-05-2 126941
16
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
17
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
18
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 2068-78-2, 57-22-7 5978
19
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23214-92-8 31703
20
Pegaspargase Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 130167-69-0
21
Azacitidine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 320-67-2 9444
22
Decitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 2353-33-5 451668
23
Cladribine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 4291-63-8 20279
24
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 33419-42-0 36462
25
Teniposide Approved Phase 4,Phase 3,Phase 2 29767-20-2 34698
26
Thioguanine Approved Phase 4,Phase 3,Phase 2,Phase 1 154-42-7 2723601
27
Vindesine Approved Phase 4,Phase 3,Phase 2 59917-39-4, 53643-48-4 40839
28
Ifosfamide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 3778-73-2 3690
29
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 53-03-2 5865
30
Aprepitant Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 170729-80-3 151165 6918365
31
Fosaprepitant Approved Phase 4,Phase 3,Phase 2,Phase 1 172673-20-0 219090
32
Acitretin Approved Phase 4 55079-83-9 6437841 5284513
33
Chlorambucil Approved Phase 4,Phase 3,Phase 2,Phase 1 305-03-3 2708
34
Topotecan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 119413-54-6, 123948-87-8 60700
35
Amphotericin B Approved, Investigational Phase 4,Phase 3,Phase 2 1397-89-3 14956 5280965
36
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
37
Amsacrine Approved Phase 4,Phase 3,Phase 2,Phase 1 51264-14-3 2179
38
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-23-7 5754 657311
39
Dasatinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 302962-49-8 3062316
40
Aldesleukin Approved Phase 4,Phase 3,Phase 2,Phase 1 85898-30-2, 110942-02-4
41
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 75614-87-8, 51-45-6 774
42
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-61-6, 62-31-7 681
43
Oprelvekin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 145941-26-0
44
Granisetron Approved, Investigational Phase 4 109889-09-0 3510
45
Palonosetron Approved, Investigational Phase 4,Phase 2 135729-61-2, 119904-90-4, 135729-56-5 148211
46
Ketamine Approved, Vet_approved Phase 4,Phase 3 6740-88-1 3821
47
Voriconazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 137234-62-9 71616
48
Busulfan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 55-98-1 2478
49 Thiotepa Approved Phase 4,Phase 3,Phase 2,Phase 1 52-24-4 5453
50
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767

Interventional clinical trials:

(show top 50) (show all 5938)

id Name Status NCT ID Phase Drugs
1 AIDA2000 - Risk-Adapted Therapy for Patients With Acute Promyelocytic Leukemia Unknown status NCT00180128 Phase 4 all-trans retinoid acid;idarubicin;mitoxantrone;daunorubicin;cytarabine
2 Treatment Protocol for Relapsed Acute Promyelocytic Leukemia (APL) With Arsenic Unknown status NCT00196768 Phase 4 Arsenic trioxide;Trisenox
3 Idarubicin at Different Dosages as Induction Therapy for Newly Diagnosed Acute Myeloid Leukaemia Unknown status NCT02277847 Phase 4 Idarubicin(8mg/m2) and cytosine arabinoside;Idarubicin(10mg/m2), cytosine arabinoside
4 Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia. Unknown status NCT00131313 Phase 4 Nipent, Cytoxan, Rituxan
5 AML1-ETO Acute Myeloid Leukemia With Fludarabine and Cytarabine Chemotherapy Unknown status NCT02024308 Phase 4 Fludarabine;Cytarabine
6 Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid Leukemia Unknown status NCT02317159 Phase 4 Imatinib
7 German Multicenter Trial for Treatment of Elderly Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Unknown status NCT00198978 Phase 4 Cyclophosphamide;Dexamethasone / Prednisolone;Cytarabine;Idarubicin;Granulocyte-Colony-Stimulating Factor;Mercaptopurine;Methotrexate;Rituximab;HDARAC;Vincristine;Depocyte;Asparaginase
8 Treatment Protocol of Children With Philadelphia Chromosome Negative High Risk Acute Lymphoblastic Leukemia Unknown status NCT01990807 Phase 4 Idarubicin(IDA)
9 Medical Research Council (MRC) Working Party on Leukaemia in Children UK National Acute Lymphoblastic Leukaemia (ALL) Trial: UKALL 2003 Unknown status NCT00222612 Phase 4 Standard childhood UK ALL protocol;Intensified treatment including Capizzi maintenance
10 3 Anthracyclines, 2 Types of Consolidation With Different ARA-C Doses and Maintenance in Adult Acute Myeloid Leukemia Unknown status NCT01587430 Phase 4 high dose ARA-C;standard dose ARA-C
11 Decitabine for Myelodysplastic Syndromes and Acute Myeloid Leukemia Before Allogeneic Hematopoietic Cell Transplantation Unknown status NCT01806116 Phase 4 decitabine
12 German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003) Unknown status NCT00198991 Phase 4 Cyclophosphamide;Dexamethasone;Vincristine;daunorubicin;Asparaginase;Methotrexate;Cytarabine;Mercaptopurine;G-CSF;Vindesine;VP16;Prednisolone;Adriamycin;Thioguanine;VM26;Idarubicin;Fludarabine;Cladribine
13 Assessment Of Gh-Igf-1 Axis In Children With Chronic Myelogenous Leukemia (CML) In Remission Unknown status NCT01901666 Phase 4 Growth Hormone
14 Compliance: Role Emerges for Success in Chronic Myelogenous Leukaemia (CML): Evaluation aND Optimisation Unknown status NCT01243489 Phase 4
15 Poly(Ethylene Glycol)(PEG)-Asparaginase During Two Treatment Courses Unknown status NCT00192673 Phase 4 PEG-asparaginase
16 HD-Idarubicin/Etoposide Intensified Conditioning Regimen Allo-HSCT for Adult ALL Unknown status NCT01873807 Phase 4 IDA;CTX;VP-16
17 Efficacy of G-CSF-Priming in Elderly AML Patients Unknown status NCT00199147 Phase 4 Cytarabine;Etoposide;Idarubicin;G-CSF;Fludarabine
18 Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults Unknown status NCT00797810 Phase 4 Rituximab
19 ATG Could Improve the Outcome Of Hematopoietic Stem Cell Transplant in Patients With Highly Aggressive T Cell Tumors Unknown status NCT02290132 Phase 4 Rabbit Anti-human Thymocyte Globulin (ATG)
20 Self-control Trial to Evaluate the Role of Aprepitant in the Prophylaxis of Post-lumbar-punture-headache (PLPH) Unknown status NCT02347878 Phase 4 Aprepitant
21 Low-Dose (17.5 mg/Day) Acitretin: Comparable Efficacy Without the Side Effects? Unknown status NCT01228409 Phase 4 Acitretin 17.5 mg/day
22 Study to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With SubOptimal Response Completed NCT01043874 Phase 4 Nilotinib
23 LAM07: Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML) Completed NCT01041040 Phase 4 gemtuzumab
24 Observational Study in Participants With Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM) and Non-Hodgkin's Lymphoma (NHL) in Latin America Completed NCT02559583 Phase 4
25 A Study of MabThera Added to Bendamustine or Chlorambucil in Patients With Chronic Lymphocytic Leukemia (MaBLe) Completed NCT01056510 Phase 4 bendamustine;chlorambucil;rituximab [MabThera/Rituxan]
26 Treatment of the Acute Myeloblastic Leukaemia in Patients Over 65 Years Completed NCT00464217 Phase 4 ARA-C;Idarubicin;Leucomax
27 Treatment of Elderly Patients (>65 Years) With Acute Lymphoblastic Leukemia Completed NCT00199095 Phase 4 Adriamycin;Cyclophosphamide;Cytarabine;Dexamethasone;Idarubicin;Ifosfamide;Methotrexate;Mercaptopurine;VM26;Vincristine
28 Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO) Completed NCT00504764 Phase 4 Arsenic Trioxide;ATRA
29 Fludarabine, Cytarabine, Topotecan in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Completed NCT00488709 Phase 4 Topotecan;Fludarabine;Cytarabine
30 Treatment of Acute Promyelocytic Leukemia With All-Trans Retinoic Acid (ATRA) and Idarubicin (AIDA) Completed NCT00465933 Phase 4 AIDA
31 Pulses of Vincristine and Dexamethasone in BFM Protocols for Children With Acute Lymphoblastic Leukemia Completed NCT00411541 Phase 4 vincristine;dexamethasone
32 PROPHYSOME: Pilot Study on Safety of a Weekly Administration of 10mg/kg of AmBisome® in Antifungal Prophylaxis Treatment of Allogeneic Stem-cell Transplantation and Acute Leukaemia Completed NCT00362544 Phase 4 Ambisome
33 Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec®-Interferon Alpha in the Treatment of Chronic-Phase Chronic Myeloid Leukaemia Completed NCT00390897 Phase 4 Glivec;Interferon
34 AML2003 - Standard-Therapy vs Intensified Therapy for Adult Acute Myeloid Leukemia Patients <= 60 Years Completed NCT00180102 Phase 4 Cytarabine vs. Cytarabine+Amsacrine+Mitoxantrone
35 Treatment of Newly Diagnosed Patients With Acute Promyelocytic Leukemia (PETHEMA LPA 2005) Completed NCT00408278 Phase 4 ATRA;Idarubicina;Mitoxantrone;ARA-C
36 PETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia Completed NCT00494897 Phase 4 Asparaginase;Cyclophosphamide;Cytarabine;Daunorubicin;Mercaptopurine;Prednisone;Vincristine;Methotrexate
37 Rituximab Plus Chemotherapy for CD20+ Adult Acute Lymphoblastic Leukemia Completed NCT01358253 Phase 4 Cyclophosphamide;Doxorubicin;Vincristine;Dexamethasone;Cytarabine;Methotrexate;Rituximab;6-Mercaptopurine;Prednisone;L-asparaginase
38 Antiviral Treatment of Chronic Lymphocytic Leukemia Completed NCT01255644 Phase 4 Valganciclovir
39 Study of Oral AMN107 (Nilotinib) in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Previously Enrolled to CAMN107A2109 Trial Completed NCT01368523 Phase 4 nilotinib
40 LAL-AR-N-2005:Study Treatment for Children High Risk Acute Lymphoblastic Leukemia Completed NCT00526409 Phase 4 Prednisolone;Daunorubicin;Vincristine;L-Asparaginase;Cyclophosphamide;Methotrexate;Cytosine Arabinoside
41 A Study of Rituximab in Combination With Fludarabine and Cyclophosphamide in Participants With Chronic Lymphocytic Leukemia and Favorable Somatic Status Completed NCT01271010 Phase 4 Cyclophosphamide;Fludarabine;Rituximab
42 Study of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to Imatinib Completed NCT00644878 Phase 4 Nilotinib
43 A Study to Compare Mabthera (Rituximab), Fludarabine and Cyclophosphamide to Mabthera and Chlorambucil in Patients With Chronic Lymphocytic Leukemia and Unfavourable Somatic Status Completed NCT01283386 Phase 4 chlorambucil;cyclophosphamide;fludarabine;rituximab [MabThera]
44 LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive Completed NCT00526305 Phase 4 Vincristine;Daunorubicin;Prednisone;L-Asparaginase;Mitoxantrone;Cytosine Arabinoside;Hydrocortisone;Mercaptopurine;Cyclophosphamide;Dexamethasone
45 A Study to Confirm the Efficacy and Safety of Fludarabine Phosphate Administered in Untreated Chronic Lymphocytic Leukemia Patients With Anemia and/or Thrombocytopenia Completed NCT00220311 Phase 4 Fludarabine Phosphate (Fludara)
46 Treatment of Acute Myeloblastic Leukemia in Younger Patients Completed NCT00390715 Phase 4 chemotherapy
47 SMD_FLAG-IDA_98: FLAG-IDA in Induction Treatment of High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic Leukemia Completed NCT00487448 Phase 4 Fludarabine;Cytarabine;G-CSF;Idarubicin
48 Study of Treatment With Nilotinib in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Completed NCT00786812 Phase 4 Nilotinib
49 ALL-REZ BFM 2002: Multi-Center Study for Children With Relapsed Acute Lymphoblastic Leukemia Completed NCT00114348 Phase 4
50 Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib Completed NCT01660906 Phase 4 Dasatinib

Search NIH Clinical Center for Leukemia

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Leukemia cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: leukemia

Genetic Tests for Leukemia

Genetic tests related to Leukemia:

id Genetic test Affiliating Genes
1 Leukemia 29

Anatomical Context for Leukemia

MalaCards organs/tissues related to Leukemia:

39
Myeloid, T Cells, B Cells, Bone, Bone Marrow, Monocytes, Lung

Publications for Leukemia

Articles related to Leukemia:

(show top 50) (show all 28308)
id Title Authors Year
1
Blinatumomab (Blincyto): lessons learned from the bispecific t-cell engager (BiTE) in acute lymphocytic leukemia (ALL). ( 28379283 )
2017
2
Coexisting and cooperating mutations in NPM1-mutated acute myeloid leukemia. ( 28152414 )
2017
3
Juvenile myelomonocytic leukemia-associated variants are associated with neo-natal lethal Noonan syndrome. ( 28098151 )
2017
4
Chemotherapy during Pregnancy: Cases of Hodgkin's and Non-Hodgkin's Lymphoma, Chronic Myeloid Leukemia, Breast Cancer, Nasopharyngeal Cancer, and Choriocarcinoma. ( 28700986 )
2017
5
DNMT3A mutations are associated with inferior overall and leukemia-free survival in chronic myelomonocytic leukemia. ( 27733013 )
2017
6
Blastic Transformation in Mexican Population With Chronic Myelomonocytic Leukemia. ( 28842140 )
2017
7
Feasibility of Lenalidomide Therapy for Persistent Chronic Lymphocytic Leukemia after Allogeneic Transplantation. ( 28495642 )
2017
8
Cooperation of MLL/AF10(OM-LZ) with PTPN11 activating mutation induced monocytic leukemia with a shorter latency in a mouse bone marrow transplantation model. ( 27859216 )
2017
9
Successful second allogeneic stem cell transplantation in a patient with T-lymphoblastic leukemia (T-ALL) relapsed as myeloid sarcoma. ( 28451803 )
2017
10
Novel agents for the treatment of childhood leukemia: an update. ( 28740405 )
2017
11
Tyrosine Kinase Inhibitor for Treatment of Adult Allogeneic Hematopoietic Stem Cell Transplantation Candidate with Philadelphia-Positive Acute Lymphoblastic Leukemia. ( 28091401 )
2017
12
FLT3 and JAK2 Mutations in Acute Myeloid Leukemia Promote Interchromosomal Homologous Recombination and the Potential for Copy Neutral Loss of Heterozygosity. ( 28108507 )
2017
13
Expression of embryonic stem cell markers in acute myeloid leukemia. ( 28718379 )
2017
14
Prognostic and biologic significance of long non-coding RNA profiling in younger adults with cytogenetically normal acute myeloid leukemia. ( 28473620 )
2017
15
Advanced chronic myelomonocytic leukemia in elderly and frail patients managed by azacitidine in the field of clinical practice. ( 28702776 )
2017
16
Lipoxygenase Inhibitors Nordihydroguaiaretic Acid and Fungus Lecanicillum lecanii Extract Induce Death of Lymphoid Leukemia Cells. ( 28744653 )
2017
17
Acute Myeloid Leukemia With Inv(16)(p13q22) Associated With Hidden Systemic Mastocytosis: Case Report and Review of Literature. ( 28579854 )
2017
18
Small Cell Carcinoma Mimicking Acute Leukemia. ( 28794375 )
2017
19
Salvage therapy for children with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia. ( 28084041 )
2017
20
Positive and Negative Regulation of Type I Interferons by the Human T Cell Leukemia Virus Antisense Protein HBZ. ( 28768861 )
2017
21
NFATC1 activation by DNA hypomethylation in chronic lymphocytic leukemia correlates with clinical staging and can be inhibited by ibrutinib. ( 28921505 )
2017
22
Increased Mortality Among Patients With Acute Leukemia Admitted on Weekends Compared to Weekdays. ( 28864171 )
2017
23
Morphoproteomics Identifies SIRT1 and EZH2 Pathways as Commonalities in B-cell Acute Lymphoblastic Leukemia: Pathogenetic Implications and Opportunities for Therapeutic Intervention. ( 28249909 )
2017
24
Expression of the promyelocytic leukemia protein without the nuclear localization signal as a novel diagnostic marker for acute promyelocytic leukemia. ( 28075463 )
2017
25
Establishment of cell line with NK/NKT phenotype from myeloid NK cell acute leukemia. ( 28934678 )
2017
26
Proviral Features of Human T Cell Leukemia Virus Type 1 in Carriers with Indeterminate Western Blot Analysis Results. ( 28701419 )
2017
27
Eviction from the sanctuary: Development of targeted therapy against cell adhesion molecules in acute lymphoblastic leukemia. ( 28923207 )
2017
28
Acute Myeloid Leukemia in a Patient With X-linked Severe Combined Immunodeficiency. ( 28678090 )
2017
29
NOTCH1 mutations are associated with high CD49d expression in chronic lymphocytic leukemia: Link between the NOTCH1 and the NF-kB pathways. ( 28935990 )
2017
30
Network-based expression analysis reveals key genes related to glucocorticoid resistance in infant acute lymphoblastic leukemia. ( 27798768 )
2017
31
Long-term persistent donor-recipient mixed chimerism without disease recurrence after myeloablative single-unit cord blood transplantation in adult acute myeloid leukemia following myelodysplastic syndrome. ( 28509586 )
2017
32
Increased SHISA3 expression characterizes chronic lymphocytic leukemia patients sensitive to lenalidomide. ( 28639485 )
2017
33
The Marine Natural Product Pseudopterosin Blocks Cytokine Release of Triple-Negative Breast Cancer and Monocytic Leukemia Cells by Inhibiting NF-I_B Signaling. ( 28832545 )
2017
34
Methylation level of CpG islands in GGH gene promoter in pediatric acute leukemia. ( 28278270 )
2017
35
Successful Intrathecal Chemotherapy Combined with Radiotherapy Followed by Pomalidomide and Low-Dose Dexamethasone Maintenance Therapy for a Primary Plasma Cell Leukemia Patient. ( 28286633 )
2017
36
Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia. ( 28494506 )
2017
37
Translocation t(8;14)(q24;q11) with concurrent PTEN alterations and deletions of STIL/TAL1 and CDKN2A/B in a pediatric case of acute T-lymphoblastic leukemia: A genetic profile associated with adverse prognosis. ( 27759908 )
2017
38
Obinutuzumab is Effective in Chronic Lymphocytic Leukemia and Rheumatoid Arthritis After Rituximab Failure: A Case Report. ( 28487504 )
2017
39
CD70/CD27 signaling promotes blast stemness and is a viable therapeutic target in acute myeloid leukemia. ( 28031480 )
2017
40
Mast cell leukemia (MCL): Clinico-pathologic and molecular features and survival outcome. ( 28599188 )
2017
41
Emerging therapies for acute myeloid leukemia: translating biology into the clinic. ( 28931762 )
2017
42
Glutaminase inhibition improves FLT3 inhibitor therapy for acute myeloid leukemia. ( 28947392 )
2017
43
The hypomorphic TERT A1062T variant is associated with increased treatment-related toxicity in acute myeloid leukemia. ( 28331964 )
2017
44
HLA-E mismatch is associated with better hematopoietic stem cell transplantation outcome in acute leukemia patients. ( 28883078 )
2017
45
Subcellular localization of the FLT3-ITD oncogene plays a significant role in the production of NOX- and p22(phox)-derived reactive oxygen species in acute myeloid leukemia. ( 27870947 )
2017
46
A phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphoma. ( 28103725 )
2017
47
Clinical impact of galectin-3 in newly diagnosed t (15;17)(q22;q21)/PML-RARa acute promyelocytic leukemia treated with all-trans retinoic acid and arsenic trioxide-based regimens. ( 28238096 )
2017
48
Forced expression of Wnt antagonists sFRP1 and WIF1 sensitizes chronic myeloid leukemia cells to tyrosine kinase inhibitors. ( 28468589 )
2017
49
The dual specificity PI3K/mTOR inhibitor PKI-587 displays efficacy against T-cell acute lymphoblastic leukemia (T-ALL). ( 28159681 )
2017
50
JAK/STAT pathway inhibition overcomes IL7-induced glucocorticoid resistance in a subset of human T-cell acute lymphoblastic leukemias. ( 28484265 )
2017